about
Exosomes-mediate microRNAs transfer in breast cancer chemoresistance regulationComparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS study.A portrait of single and multiple HPV type infections in Brazilian women of different age strata with squamous or glandular cervical lesionsNatural Killer Cells Response to IL-2 Stimulation Is Distinct between Ascites with the Presence or Absence of Malignant Cells in Ovarian Cancer Patients.Low expression of human histocompatibility soluble leukocyte antigen-G (HLA-G5) in invasive cervical cancer with and without metastasis, associated with papilloma virus (HPV).Criteria for selection of laparoscopy for women with adnexal mass.Aluminum concentrations in central and peripheral areas of malignant breast lesions do not differ from those in normal breast tissuesStaging recurrent ovarian cancer with (18)FDG PET/CT.Survival of women with ovarian carcinomas and borderline tumors is not affected by estrogen and progesterone receptor status.Bayesian estimation of performance measures of cervical cancer screening tests in the presence of covariates and absence of a gold standard.Retrieval of HPV oncogenes E6 and E7 mRNA from cervical specimens using a manual open technology protocolPolymorphisms of glutathione S-transferase Mu 1 (GSTM1), Theta 1 (GSTT1), and Pi 1 (GSTP1) genes and epithelial ovarian cancer risk.Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses.MMP-9/RECK Imbalance: A Mechanism Associated with High-Grade Cervical Lesions and Genital Infection by Human Papillomavirus and Chlamydia trachomatis.Association of HPV infection and Chlamydia trachomatis seropositivity in cases of cervical neoplasia in Midwest Brazil.VEGF gene polymorphisms and outcome of epithelial ovarian cancer patients.Cysts within Otherwise Probably Benign Solid Breast Masses and the Risk of Malignancy.Variations in the sonographic measurement techniques of BI-RADS 3 breast masses.Tissue aluminum concentration does not affect the genomic stability of ERBB2, C-MYC, and CCND1 genes in breast cancer.Association between polymorphisms in xenobiotic detoxification-related genes with prognosis of epithelial ovarian cancer.Molecular Subtypes of Breast Cancer Are Not Associated with the Clinical Under- or Overstaging of Breast Cancer.Phylogenetic classification of human papillomavirus genotypes in high-grade cervical intraepithelial neoplasia in women from a densely populated Brazilian urban region.Persistent high-risk human papillomavirus infections and other end-point markers of progressive cervical disease among women prospectively followed up in the New Independent States of the Former Soviet Union and the Latin American Screening study coPrognostic significance of PD-L1 and PD-L2 in breast cancer.Bacterial vaginosis and inflammatory response showed association with severity of cervical neoplasia in HPV-positive women.Cyclooxygenase-2 (COX2) and p53 protein expression are interdependent in breast cancer but not associated with clinico-pathological surrogate subtypes, tumor aggressiveness and patient survival.Usefulness of vaginal cytology tests in women with previous hysterectomy for benign diseases: assessment of 53,891 tests.Microinvasive adenocarcinoma of the cervix in a young woman vaccinated against human papillomavirus: the screening must be continued.Optional screening strategies for cervical cancer using standalone tests and their combinations among low- and medium-income populations in Latin America and Eastern Europe.Competing-risks regression models in analysis of biomarkers as predictors of high-risk human papillomavirus (HPV) infection outcomes and incident CIN in the LAMS cohort.Drug addiction is not an independent risk factor for oncogenic human papillomavirus infections or high-grade cervical intraepithelial neoplasia: case-control study nested within the Latin American Screening study cohort.[Performance of cervical cytology with review by different observers and hybrid capture II in the diagnosis of cervical intraepithelial neoplasia grades 2 and 3].Human papillomavirus (HPV) infections as risk factors for cytological and histological abnormalities in baseline PAP smear-negative women followed-up for 2 years in the LAMS study.Simple rules for ultrasonographic subcategorization of BI-RADS®-US 4 breast masses.Performance of Pap smear and human papilloma virus testing in the follow-up of women with cervical intraepithelial neoplasia grade 1 managed conservatively.Covariates of high-risk human papillomavirus (HPV) infections are distinct for incident CIN1, CIN2 and CIN3 as disclosed by competing-risks regression models.Up-regulation of DNAM-1 and NKp30, associated with improvement of NK cells activation after long-term culture of mononuclear cells from patients with ovarian neoplasia.Value of conventional pap smear, liquid-based cytology, visual inspection and human papillomavirus testing as optional screening tools among latin american women <35 and > or =35 years of age: experience from the Latin American Screening Study.Vascular endothelial growth factor (VEGF) polymorphism and increased risk of epithelial ovarian cancer.Self-sampling for human papillomavirus (HPV) testing as cervical cancer screening option. Experience from the LAMS study.
P50
Q28066991-5481F52C-6F96-436B-AD2F-73C8EAE2D963Q30999986-CFFC04D2-926E-4A81-B2BD-C0C52247EA73Q33608013-B0F07DDA-B5D7-4D09-B4E0-B2DBECDB64B9Q33754724-AA409B9B-A751-4CAE-B8C1-D4768FCFCE02Q33803141-818D1D61-C987-4DF6-8CC0-2B0C7A9379F6Q34132485-22F0AD76-F140-4A20-A4B8-8BCEE04A3BECQ34621639-E8AC5C62-660C-4FEE-BEB2-17091AEEA5A7Q36611758-D86607AD-6909-4C4C-ACE9-FF05255E3791Q36817508-0A0F3A33-1E04-4B7D-BBF4-645E73F0E4B6Q37055949-5BB2148E-AF84-4F15-A076-DA78B4DC9776Q37225996-D9F7566B-57FB-4145-9F4C-CAF6C8B27FCBQ37261855-FDDF8B7C-2D49-4C18-B5D0-CE0982A268DEQ37359954-624B9470-F991-440E-8086-8EF8BFF17279Q37839559-2B0A4749-CF85-4089-8280-01B6388F8BCCQ37848816-32FD2103-3E50-45FD-8218-0796D3A55465Q38805626-9556F407-26F8-46B3-A73E-F71CF4AD2C3EQ38811950-FB000FF8-A942-445B-8A9E-E5C7A6EE65F7Q38856660-8D5EED5A-A14A-42C3-B840-3BB7B6C9368AQ39383277-5FAFA646-D9C8-40AF-850F-9C17DBABA218Q39430809-1133F8D7-1C0E-4DDE-9AA6-E2D04346775BQ39759959-392257AC-7C72-4F11-BB8B-E04E6B45C10EQ39903535-F5F1834B-31FD-4D73-B547-8D14B5A5BC2CQ39965827-FD4462A8-7845-40FC-9585-1D035EE16311Q40351696-AC8433CF-9D09-448E-A555-24CEDF7A5DB6Q40880011-7CA5841D-B6C1-4C4E-90E4-E536761E9F64Q40962219-22B3F48C-996A-4E8C-9622-EC480DA91F05Q41373168-FD516AD2-52B3-4F6D-AD29-F6BFAE85C0A2Q42253433-BAFB02E2-DA2C-4AE0-8F2A-B86992D6DE11Q42755668-B88DE293-6A67-40C5-B996-AD3F33BB151FQ43407219-505C6A88-55CF-4A66-B914-78EF501209E3Q43636743-6074573A-3D6B-4D40-9B4F-0B6CED86A5E6Q43742465-FFAEDB1B-C3E1-4134-A013-47B15CBACEC1Q43870125-E041D9DE-B751-4767-A8CC-C9D457BBEB9AQ44275265-6A66147E-30A6-48FD-8CC3-25B1D537E26BQ45417709-85E8FC82-3C5F-4214-9F55-C015F7B88913Q45710298-5DCD4F71-4F63-492B-8C89-43FE6B194D78Q45865576-A130DCA3-7902-485B-A0ED-91F6C6B0846DQ46207029-E2C1C69D-1548-4FC0-9CF2-50E1E7D97036Q46290881-8C73BA6C-F887-45C1-B714-D8691D9C1E56Q46421127-C320369D-538F-4B87-9C14-C3ED14D37AE4
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sophie F Derchain
@nl
Sophie F Derchain
@sl
Sophie F. Derchain
@en
Sophie F. Derchain
@es
type
label
Sophie F Derchain
@nl
Sophie F Derchain
@sl
Sophie F. Derchain
@en
Sophie F. Derchain
@es
prefLabel
Sophie F Derchain
@nl
Sophie F Derchain
@sl
Sophie F. Derchain
@en
Sophie F. Derchain
@es
P106
P1153
6701848441
P21
P31
P496
0000-0003-1029-9993